Ep 24: Insitro CEO Daphne Koller on Using ML to Change Drug Discovery

from Vital Signs with Jacob Effron and Nikhil Krishnan · host Daphne Koller, Jacob Effron

Jacob sits down with Insitro CEO Daphne Koller to discuss founding Coursera, where and how ML can drive the most impact in drug development, and if foundation models can transform core drug discovery work and edtech. 00:00 intro00:59 Daphne’s journey09:02 AI and biology discovery10:42 insitro vs. traditional pharma19:47 phenotyping patients25:44 early mistakes29:34 the future of data35:16 partnering with larger pharma companies38:00 impact of LLMs on biopharma43:47 over-hyped/under-hyped

Episode metadata supplied by the publisher feed · Published Jun 13, 2023

Embed this episode

Attribution link and audio player

What this episode covers

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Ep 24: Insitro CEO Daphne Koller on Using ML to Change Drug Discovery

0:00 48:50

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Vital Signs with Jacob Effron and Nikhil Krishnan?

This episode is 48 minutes long.

When was this Vital Signs with Jacob Effron and Nikhil Krishnan episode published?

This episode was published on June 13, 2023.

Can I download this Vital Signs with Jacob Effron and Nikhil Krishnan episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!